Literature DB >> 31637482

Good clinical practice recommendations for the use of PET/CT in oncology.

Pierre-Yves Salaün1, Ronan Abgral2, Olivier Malard3, Solène Querellou-Lefranc2, Gilles Quere4, Myriam Wartski5, Romain Coriat6, Elif Hindie7, David Taieb8, Antoine Tabarin9, Antoine Girard10, Jean-François Grellier11, Isabelle Brenot-Rossi12, David Groheux13, Caroline Rousseau14, Désirée Deandreis15, Jean-Louis Alberini16, Caroline Bodet-Milin17, Emmanuel Itti18, Olivier Casasnovas19, Françoise Kraeber-Bodere14,17, Philippe Moreau20, Arnaud Philip21, Corinne Balleyguier22, Alain Luciani23, Florent Cachin24.   

Abstract

Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French practice on the use of PET in oncology was framed in recommendations based on Standards-Options-Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing good clinical practice recommendations. These good clinical practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status-the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.

Entities:  

Keywords:  Computed tomography; Methodological approval; Positron emission tomography

Mesh:

Year:  2019        PMID: 31637482     DOI: 10.1007/s00259-019-04553-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  27 in total

1.  Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.

Authors:  Tobias Maurer; Jürgen E Gschwend; Isabel Rauscher; Michael Souvatzoglou; Bernhard Haller; Gregor Weirich; Hans-Jürgen Wester; Matthias Heck; Hubert Kübler; Ambros J Beer; Markus Schwaiger; Matthias Eiber
Journal:  J Urol       Date:  2015-12-09       Impact factor: 7.450

2.  Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology.

Authors:  John W Yaxley; Sheliyan Raveenthiran; François-Xavier Nouhaud; Hemamali Samartunga; Anna J Yaxley; Geoff Coughlin; Brett Delahunt; Lars Egevad; Louise McEwan; David Wong
Journal:  J Urol       Date:  2019-04       Impact factor: 7.450

3.  Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.

Authors:  Seong-Jang Kim; Sang-Woo Lee; Hong Koo Ha
Journal:  Urol Int       Date:  2018-09-28       Impact factor: 2.089

4.  68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study.

Authors:  Eva Dyrberg; Helle W Hendel; Tri Hien Viet Huynh; Tobias Wirenfeldt Klausen; Vibeke B Løgager; Claus Madsen; Erik M Pedersen; Maria Pedersen; Henrik S Thomsen
Journal:  Eur Radiol       Date:  2018-08-21       Impact factor: 5.315

5.  [18F]-DCFPyL Positron Emission Tomography/Magnetic Resonance Imaging for Localization of Dominant Intraprostatic Foci: First Experience.

Authors:  Glenn Bauman; Peter Martin; Jonathan D Thiessen; Reggie Taylor; Madeleine Moussa; Mena Gaed; Irina Rachinsky; Zahra Kassam; Joseph Chin; Stephen Pautler; Ting Yim Lee; John F Valliant; Aaron Ward
Journal:  Eur Urol Focus       Date:  2016-10-26

6.  Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis.

Authors:  Ricardo Pereira Mestre; Giorgio Treglia; Matteo Ferrari; Mariarosa Pascale; Calogero Mazzara; Ngwa Che Azinwi; Anna Llado'; Anastasios Stathis; Luca Giovanella; Enrico Roggero
Journal:  Eur J Clin Invest       Date:  2019-01-11       Impact factor: 4.686

7.  Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography.

Authors:  Reinhard Bos; Jacobus J M van Der Hoeven; Elsken van Der Wall; Petra van Der Groep; Paul J van Diest; Emile F I Comans; Urvi Joshi; Gregg L Semenza; Otto S Hoekstra; Adriaan A Lammertsma; Carla F M Molthoff
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

8.  Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.

Authors:  Olivier Humbert; Alina Berriolo-Riedinger; Alexandre Cochet; Mélanie Gauthier; Céline Charon-Barra; Séverine Guiu; Isabelle Desmoulins; Michel Toubeau; Inna Dygai-Cochet; Charles Coutant; Pierre Fumoleau; François Brunotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-21       Impact factor: 9.236

9.  Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.

Authors:  David Pfister; Daniel Porres; Axel Heidenreich; Isabel Heidegger; Ruth Knuechel; Florian Steib; Florian F Behrendt; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-19       Impact factor: 9.236

10.  Distribution of prostate nodes: a PET/CT-derived anatomic atlas of prostate cancer patients before and after surgical treatment.

Authors:  Nina-Sophie Hegemann; Vera Wenter; Sonja Spath; Nadia Kusumo; Minglun Li; Peter Bartenstein; Wolfgang P Fendler; Christian Stief; Claus Belka; Ute Ganswindt
Journal:  Radiat Oncol       Date:  2016-03-11       Impact factor: 3.481

View more
  18 in total

1.  Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

Authors:  Caroline Rousseau; David M Goldenberg; Mathilde Colombié; Jean-Charles Sébille; Philippe Meingan; Ludovic Ferrer; Pierre Baumgartner; Evelyne Cerato; Damien Masson; Mario Campone; Aurore Rauscher; Vincent Fleury; Catherine Labbe; Alain Faivre Chauvet; Jean-Sebastien Fresnel; Claire Toquet; Jacques Barbet; Robert M Sharkey; Loic Campion; Françoise Kraeber-Bodéré
Journal:  J Nucl Med       Date:  2020-03-13       Impact factor: 10.057

2.  Clinical perspectives for the use of total body PET/CT.

Authors:  Ronan Abgral; David Bourhis; Pierre-Yves Salaun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06       Impact factor: 9.236

3.  Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.

Authors:  Y Touchefeu; C Bailly; E Frampas; T Eugène; C Rousseau; M Bourgeois; C Bossard; A Faivre-Chauvet; A Rauscher; D Masson; A David; E Cerato; T Carlier; R M Sharkey; D M Goldenberg; J Barbet; F Kraeber-Bodere; C Bodet-Milin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08-21       Impact factor: 9.236

4.  Interobserver agreement of 18F-Fluorodeoxyglucose Positron-Emission Tomography combined with low-dose Computed Tomography for occult cancer screening in patients with unprovoked venous thromboembolism.

Authors:  Philippe Robin; Ravinder K Grewal; Pierre-Yves Le Roux; Grégoire Le Gal; Pierre-Yves Salaun
Journal:  Thromb Res       Date:  2020-01-30       Impact factor: 3.944

5.  EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA).

Authors:  Roberto C Delgado Bolton; Nicolas Aide; Patrick M Colletti; Annamaria Ferrero; Diana Paez; Andrea Skanjeti; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-03       Impact factor: 9.236

6.  The use of systematic review evidence to support the development of guidelines for positron emission tomography: a cross-sectional survey.

Authors:  Qianrui Li; Wenxiu Hou; Ling Li; Minggang Su; Yan Ren; Wen Wang; Kang Zou; Rong Tian; Xin Sun
Journal:  Eur Radiol       Date:  2021-03-08       Impact factor: 5.315

Review 7.  The Role of Radiomics in Lung Cancer: From Screening to Treatment and Follow-Up.

Authors:  Radouane El Ayachy; Nicolas Giraud; Paul Giraud; Catherine Durdux; Philippe Giraud; Anita Burgun; Jean Emmanuel Bibault
Journal:  Front Oncol       Date:  2021-05-05       Impact factor: 6.244

8.  Impact of suboptimal dosimetric coverage of pretherapeutic 18F-FDG PET/CT hotspots on outcome in patients with locally advanced cervical cancer treated with chemoradiotherapy followed by brachytherapy.

Authors:  François Lucia; Vincent Bourbonne; Dorothy Gujral; Gurvan Dissaux; Omar Miranda; Maelle Mauguen; Olivier Pradier; Ronan Abgral; Ulrike Schick
Journal:  Clin Transl Radiat Oncol       Date:  2020-05-11

9.  Use of Baseline 18 F-FDG PET/CT to Identify Initial Sub-Volumes Associated With Local Failure After Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer.

Authors:  François Lucia; Omar Miranda; Ronan Abgral; Vincent Bourbonne; Gurvan Dissaux; Olivier Pradier; Mathieu Hatt; Ulrike Schick
Journal:  Front Oncol       Date:  2020-05-07       Impact factor: 6.244

10.  Head-to-head evaluation of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma.

Authors:  Bingxin Gu; Xin Liu; Shuoer Wang; Xiaoping Xu; Xiaosheng Liu; Silong Hu; Wangjun Yan; Zhiguo Luo; Shaoli Song
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-03       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.